- Home
- FLGC vs EVAX Comparison
FLGC vs EVAX Comparison
Compare FLGC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- EVAX
- Stock Information
- Founded
- FLGC 2019
- EVAX 2008
- Country
- FLGC United States
- EVAX Denmark
- Employees
- FLGC N/A
- EVAX N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLGC Health Care
- EVAX Health Care
- Exchange
- FLGC Nasdaq
- EVAX Nasdaq
- Market Cap
- FLGC 17.3M
- EVAX 16.3M
- IPO Year
- FLGC 2021
- EVAX 2021
- Fundamental
- Price
- FLGC $0.59
- EVAX $1.69
- Analyst Decision
- FLGC Strong Buy
- EVAX Strong Buy
- Analyst Count
- FLGC 4
- EVAX 3
- Target Price
- FLGC $5.67
- EVAX $33.33
- AVG Volume (30 Days)
- FLGC 117.8K
- EVAX 64.3K
- Earning Date
- FLGC 05-13-2025
- EVAX 05-27-2025
- Dividend Yield
- FLGC N/A
- EVAX N/A
- EPS Growth
- FLGC N/A
- EVAX N/A
- EPS
- FLGC N/A
- EVAX N/A
- Revenue
- FLGC $59,505,000.00
- EVAX $3,295,000.00
- Revenue This Year
- FLGC $4.28
- EVAX $9,039.73
- Revenue Next Year
- FLGC N/A
- EVAX $1.47
- P/E Ratio
- FLGC N/A
- EVAX N/A
- Revenue Growth
- FLGC N/A
- EVAX N/A
- 52 Week Low
- FLGC $0.59
- EVAX $1.64
- 52 Week High
- FLGC $2.75
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- FLGC 35.15
- EVAX 37.17
- Support Level
- FLGC $0.59
- EVAX $1.68
- Resistance Level
- FLGC $0.72
- EVAX $1.97
- Average True Range (ATR)
- FLGC 0.05
- EVAX 0.11
- MACD
- FLGC 0.00
- EVAX 0.05
- Stochastic Oscillator
- FLGC 3.85
- EVAX 23.33
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.